South Korea · Delayed Price · Currency is KRW Genomictree Statistics
Total Valuation
Genomictree has a market cap or net worth of KRW 308.69 billion. The enterprise value is 233.67 billion.
| Market Cap | 308.69B |
| Enterprise Value | 233.67B |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Genomictree has 24.50 million shares outstanding. The number of shares has increased by 0.43% in one year.
| Current Share Class | 24.50M |
| Shares Outstanding | 24.50M |
| Shares Change (YoY) | +0.43% |
| Shares Change (QoQ) | +1.45% |
| Owned by Insiders (%) | 15.72% |
| Owned by Institutions (%) | 0.16% |
| Float | 20.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 80.70 |
| PB Ratio | 2.50 |
| P/TBV Ratio | 2.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 61.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 56.88, with a Debt / Equity ratio of 0.00.
| Current Ratio | 56.88 |
| Quick Ratio | 56.05 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | -31.99 |
Financial Efficiency
Return on equity (ROE) is -6.67% and return on invested capital (ROIC) is -23.97%.
| Return on Equity (ROE) | -6.67% |
| Return on Assets (ROA) | -5.22% |
| Return on Invested Capital (ROIC) | -23.97% |
| Return on Capital Employed (ROCE) | -8.51% |
| Weighted Average Cost of Capital (WACC) | 4.61% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.03 |
| Inventory Turnover | 9.46 |
Taxes
In the past 12 months, Genomictree has paid 11.47 million in taxes.
| Income Tax | 11.47M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -3.15% in the last 52 weeks. The beta is 0.05, so Genomictree's price volatility has been lower than the market average.
| Beta (5Y) | 0.05 |
| 52-Week Price Change | -3.15% |
| 50-Day Moving Average | 15,477.00 |
| 200-Day Moving Average | 20,931.75 |
| Relative Strength Index (RSI) | 38.69 |
| Average Volume (20 Days) | 122,600 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genomictree had revenue of KRW 3.83 billion and -8.02 billion in losses. Loss per share was -333.14.
| Revenue | 3.83B |
| Gross Profit | 837.60M |
| Operating Income | -10.60B |
| Pretax Income | -8.16B |
| Net Income | -8.02B |
| EBITDA | -9.55B |
| EBIT | -10.60B |
| Loss Per Share | -333.14 |
Balance Sheet
The company has 75.39 billion in cash and 55.19 million in debt, with a net cash position of 75.33 billion or 3,074.76 per share.
| Cash & Cash Equivalents | 75.39B |
| Total Debt | 55.19M |
| Net Cash | 75.33B |
| Net Cash Per Share | 3,074.76 |
| Equity (Book Value) | 123.47B |
| Book Value Per Share | 5,053.89 |
| Working Capital | 75.79B |
Cash Flow
In the last 12 months, operating cash flow was -10.64 billion and capital expenditures -2.80 billion, giving a free cash flow of -13.44 billion.
| Operating Cash Flow | -10.64B |
| Capital Expenditures | -2.80B |
| Depreciation & Amortization | 1.05B |
| Net Borrowing | -56.21M |
| Free Cash Flow | -13.44B |
| FCF Per Share | -548.53 |
Margins
Gross margin is 21.90%, with operating and profit margins of -277.10% and -209.77%.
| Gross Margin | 21.90% |
| Operating Margin | -277.10% |
| Pretax Margin | -213.27% |
| Profit Margin | -209.77% |
| EBITDA Margin | -249.62% |
| EBIT Margin | -277.10% |
| FCF Margin | n/a |
Dividends & Yields
Genomictree does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.43% |
| Shareholder Yield | -0.43% |
| Earnings Yield | -2.60% |
| FCF Yield | -4.35% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 14, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Sep 14, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Genomictree has an Altman Z-Score of 112.56 and a Piotroski F-Score of 3.
| Altman Z-Score | 112.56 |
| Piotroski F-Score | 3 |